CTLA4 and neoplasm: Indeed, combining mTORC1/mTORC2 inhibitor vistusertib with different immune-checkpoint blockades, including anti-PD-1, anti-PD-L1 or anti-CTLA-4, significantly reduced MC38 or CT-26 tumor growth compared to monotherapies [105].